References
- Sharma, P. and J.P. Allison, The future of immune checkpoint therapy. Science, 2015. 348(6230): p. 56-61.
- Dunn, G.P., C.M. Koebel, and R.D. Schreiber, Interferons, immunity and cancer immunoediting. Nat Rev Immunol, 2006. 6(11): p. 836-48.
- Galon, J., Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorc-Pages C, et al., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 2006. 313(5795): p. 1960-4.
- Schreiber R.D., Old LJ, Smyth ML, Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011 Mar 25;331(6024):1565-70
- Galon, J., Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, et al., Cancer classification using the Immunoscore: a worldwide task force. J Transl Med, 2012 Oct 3;10: p. 205.
- Galon, J., Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al., Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol, 2014. 232(2): p. 199-209.
- Baxevanis, C.N., M. Papamichail, and S.A. Perez, Immune classification of colorectal cancer patients: impressive but how complete? Expert OpinBiolTher, 2013. 13(4): p. 517-26.
- Becht, E., Giraldo NA, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH, Cancer immune contexture and immunotherapy. CurrOpinImmunol, 2015. 39: p. 7-13
- Krummel, M.F. and J.P. Allison, CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med, 1996. 183(6): p. 2533-40.
- Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012. 12(4): p. 252-64.
- Schneider, H., Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al., Reversal of the TCR stop signal by CTLA-4. Science, 2006. 313(5795): p. 1972-5.
- Qureshi, O.S., Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, et al., Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science, 2011. 332(6029): p. 600-3.
- Fecher, L.A., Agarwala SS, Hodi FS, Weber JS:Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist, 2013. 18(6): p. 733-43.
- Ivashko, I.N. and J.M. Kolesar, Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. Am J Health Syst Pharm, 2016. 73(4): p. 193-201.
- Topalian, S.L., Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 2012. 366(26): p. 2443-54.
- Hamid, O., Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med, 2013. 369(2): p. 134-44.
- Butte, M.J., Keir ME, Phamduy TB, Sharpe AH, Freeman GJ., Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity, 2007. 27(1): p. 111-22.
- Brahmer, J.R., Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med, 2012. 366(26): p. 2455-65.
- Taube, J.M., Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al., Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med, 2012. 4(127): p. 127ra37.
- Herbst, R.S., Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014. 515(7528): p. 563-7.
- Llosa, N.J., Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM et al., The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov, 2015. 5(1): p. 43-51.
- Powles, T., Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al., MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014. 515(7528): p. 558-62.
- Rizvi, N.A., Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 2015. 348(6230): p. 124-8.
- Taube, J.M., Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res, 2014. 20(19): p. 5064-74.
- Carbognin, L., Pilotto S, Milella M, Vaccaro V, Brunelli M, Caliò A, et al., Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One, 2015. 10(6): p. e0130142.
- Gainor, J., et al., Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC). J Clin Oncol 2015. 33(_suppl): p. abstr 8012.
- Watson, I.R., Takahashi K, Futreal PA, Chin L., Emerging patterns of somatic mutations in cancer. Nat Rev Genet, 2013. 14(10): p. 703-18.
- Yadav, M., Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al., Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature, 2014. 515(7528): p. 572-6.
- Schumacher, T.N. and R.D. Schreiber, Neoantigens in cancer immunotherapy. Science, 2015. 348(6230): p. 69-74.
- Gubin, M.M., Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al., Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature, 2014. 515(7528): p. 577-81.
- Boussiotis, V.A., Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma. N Engl J Med, 2014. 371(23): p. 2230-2.
- Snyder, A., Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al., Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med, 2014. 371(23): p. 2189-99.
- Lawrence, M.S., Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 2013. 499(7457): p. 214-8.
- Guinney, J., Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al., The consensus molecular subtypes of colorectal cancer. Nat Med, 2015. 21(11): p. 1350-6.
- Segal, N.H. and L.B. Saltz, Translational considerations on the outlook of immunotherapy for colorectal cancer. Curr Colorectal Cancer Rep 2015. 11: p. 92-97.
- Wang, J., Tang C, Zhang L, Gong Y, Yin C, Li Y, Compressing with dominant hand improves quality of manual chest compressions for rescuers who performed suboptimal CPR in manikins. Am J Emerg Med, 2015. 33(7): p. 931-6.
- Le, D.T., Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med, 2015. 372(26): p. 2509-20.
- Chia, N.Y. and P. Tan, Molecular Classification of Gastric Cancer. Ann Oncol, 2016.
- Muro, K., et al., Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-0120.. J Clin Oncol, 2015. 33(3_suppl): p. 3.
- Ott, P., et al., Pembrolizumab (MK-3475) For PD-L1–Positive Squamous Cell Carcinoma of the Anal Canal: Preliminary Safety and Efficacy Results From KEYNOTE-028. Eur J Cancer, 2015. 51(3_suppl): p. abstr 500.
- Fearon, D.T., The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol Res, 2014. 2(3): p. 187-93.
- Le, D.T., Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, et al., Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol, 2015. 33(12): p. 1325-33.
- El-Khoueiry, A., et al., Phase I/II Safety and Antitumor Activity of Nivolumab in Patients with Advanced Hepatocellular Carcinoma (HCC): CA209-040. J Clin Oncol, 2015. 33(_suppl): p. abstr LBA101.
- Coosemans, A., T. Baert, and I. Vergote, A view on dendritic cell immunotherapy in ovarian cancer: how far have we come? Facts Views Vis Obgyn, 2015. 7(1): p. 73-8.
- Hamanishi, J., Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al., Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol, 2015. 33(34): p. 4015-22.
- Sato, E., Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al., Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A, 2005. 102(51): p. 18538-43.
- Vermeij, R., Leffers N, Hoogeboom BN, Hamming IL, Wolf R, Reyners AK, et al., Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. Int J Cancer, 2012. 131(5): p. E670-80.
- Disis, M.L., et al: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial. J ClinOncol 33, 2015 (suppl; abstr 5509)
- Motzer, R.J., Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med, 2015. 373(19): p. 1803-13.
- O’Donnell, P., E. Plimack, and J. Bellmunt, Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study. J Clin Oncol 2015. 33(7_suppl): p. abstr 296.
- Rosenberg, J., et al., 21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 21) Eur J Cancer, 2015. 51(3_suppl): p. S120.
- Rosenberg, J., Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, 7 May 2016, vol387;10031:1909-1920
- Andrews, D.M., E. Maraskovsky, and M.J. Smyth, Cancer vaccines for established cancer: how to make them better? Immunol Rev, 2008. 222: p. 242-55.
- GuhaThakurta, D., Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ, et al., Humoral Immune Response against Non-targeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clin Cancer Res, 2015. 21(16): p. 3619-30.
- Kantoff, P.W., Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 2010. 363(5): p. 411-22.
- Sheikh, N.A., Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, et al., Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother, 2013. 62(1): p. 137-47.
- Park, J.W., Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R., Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol, 2007. 25(24): p. 3680-7.
- Senzer, N. and J. Nemunaitis, A review of contusugeneladenovec (Advexin) p53 therapy. CurrOpinMolTher, 2009. 11(1): p. 54-61.
- Kantoff, P.W., Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al., Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol, 2010. 28(7): p. 1099-105.
- Gulley, J.L., Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al., Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother, 2010. 59(5): p. 663-74.
- Garnett, C.T., Greiner JW, Tsang KY, Kudo-Saito C, Grosenbach DW, Chakraborty M, et al., TRICOM vector based cancer vaccines. Curr Pharm Des, 2006. 12(3): p. 351-61.
- Gulley, J.L., Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, et al., Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res, 2008. 14(10): p. 3060-9.
- de Gruijl, T.D., A.B. Janssen, and V.W. van Beusechem, Arming oncolytic viruses to leverage antitumor immunity. Expert Opin Biol Ther, 2015. 15(7): p. 959-71.
- Lichty, B.D., Breitbach CJ, Stojdl DF, Bell JC., Going viral with cancer immunotherapy. Nat Rev Cancer, 2014. 14(8): p. 559-67.
- Liu, B.L., Robinson M, Han ZQ, Branston RH, English C, Reay P, et al., ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther, 2003. 10(4): p. 292-303.
- Andtbacka, R.H., Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al., Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol, 2015. 33(25): p. 2780-8.
- Rajani, K.R. and R.G. Vile, Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses, 2015. 7(11): p. 5889-901.
- Wollmann, G., K. Ozduman, and A.N. van den Pol, Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J, 2012. 18(1): p. 69-81.
- Baxevanis, C.N., Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, Papamichail M., Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother, 2006. 55(1): p. 85-95.
- Holmes, J.P., Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, et al., Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol, 2008. 26(20): p. 3426-33.
- Perez, S.A., Anastasopoulou EA, Papamichail M, Baxevanis CN., AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction. Cancer Immunol Immunother, 2014. 63(11): p. 1141-50.
- Perez, S.A., Anastasopoulou EA, Tzonis P, Gouttefangeas C, Kalbacher H, Papamichail M, Baxevanis CN., AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial. Cancer Immunol Immunother, 2013. 62(10): p. 1599-608.
- Perez, S.A., Kallinteris NL, Bisias S, Tzonis PK, Georgakopoulou K, Varla-Leftherioti M, et al., Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res, 2010. 16(13): p. 3495-506.
- Greene, J., et al., Final pre-specified analysis of the phase II trial of the AE37+GM-CSF vaccine in high risk breast cancer patients to prevent recurrence. J Clin Oncol 2015. 33(_suppl): p. abstr 622.
- Pistamaltzian, N., et al., Preexisting immunity as a potential biomarker for clinical response to AE37 vaccination in breast cancer patients Annals of Oncology, 2015. 26(8_suppl): p. viii1–viii4.
- Sears, A.K., Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, et al., AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin Biol Ther, 2011. 11(11): p. 1543-50.
- Twyman-Saint Victor, C.Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al.: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015 Apr 16;520(7547):373-7.
- Cooper, Z.A., Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, et al.: Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54.
- Crittenden, M.Kohrt H, Levy R, Jones J, Camphausen K, Dicker A, et al.: Current clinical trials testing combinations of immunotherapy and radiation. SeminRadiatOncol. 2015 Jan; 25(1):54-64.
- Balachandran, V.P. Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al.: Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011 Aug 28; 17(9):1094-100.
- Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al.: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl AcadSci U S A (2003) 100(8):4712.
- Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, et al.: Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res (2014) 2(2):127.
- Zitvogel, L., Kepp, O., & Kroemer, G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev ClinOncol. 2011 Mar;8(3):151-60.
- Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance. Immunity. 2013 Jul 25; 39(1):74-88.
- Zitvogel, L., Tesniere, A., & Kroemer, G. (2006). Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat Rev Immunol. 2006 Oct; 6(10):715-27.
- Robert, C., Thomas, L., Bondarenko, I., O’Day, S., M, D. J., Garbe, C., et al.: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30; 364(26):2517-26.
- Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., et al.: Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy inextensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013 Jan; 24(1):75-83.
- Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., et al.: Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, doubleblind, multicenter phase II study. J ClinOncol. 2012 Jun 10; 30(17):2046-54.
- Antonia, S. J., Brahmer, J. R., Gettinger, S. N., Chow, L. Q., Juergens, R. A., Shepherd, F. A., et al.: Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer(NSCLC). J ClinOncol (2014); 32 (Suppl.; abstr 8113).
- Curran, M. A., & Allison, J. P.:Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject pre-implanted tumors. Cancer Res. 2009 Oct 1; 69(19):7747-55.
- Le, D. T., Lutz, E., Uram, J. N., Sugar, E. A., Onners, B., Solt, S., et al.: Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013 Sep; 36(7):382-9.
- Gerritsen, W., van den Eertwegh, A. J., de Gruijl, T., van den Berg, H. P., Scheper, R. J., Sacks, N., et al.: Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC). J ClinOncol(2008) 26(Suppl.), 5146.
- Espenschied, J., Lamont, J., Longmate, J., Pendas, S., Wang, Z., Diamond, D. J., et al.: CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol. 2003 Mar 15;170(6):3401-7.
- Chakraborty, M., Schlom, J., & Hodge, JW: The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses. Cancer Immunol Immunother. 2007 Sep; 56(9):1471-84.
- Madan, R. A., Mohebtash, M., Arlen, P. M., Vergati, M., Rauckhorst, M., Steinberg, S. M., et al.: Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. Lancet Oncol 20102 May; 13(5): 501–508.